首页> 美国卫生研究院文献>Molecular Therapy. Methods Clinical Development >Multigenic lentiviral vectors for combined and tissue-specific expression of miRNA- and protein-based antiangiogenic factors
【2h】

Multigenic lentiviral vectors for combined and tissue-specific expression of miRNA- and protein-based antiangiogenic factors

机译:多基因慢病毒载体用于基于miRNA和蛋白质的抗血管生成因子的联合和组织特异性表达

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Lentivirus-based gene delivery vectors carrying multiple gene cassettes are powerful tools in gene transfer studies and gene therapy, allowing coexpression of multiple therapeutic factors and, if desired, fluorescent reporters. Current strategies to express transgenes and microRNA (miRNA) clusters from a single vector have certain limitations that affect transgene expression levels and/or vector titers. In this study, we describe a novel vector design that facilitates combined expression of therapeutic RNA- and protein-based antiangiogenic factors as well as a fluorescent reporter from back-to-back RNApolII-driven expression cassettes. This configuration allows effective production of intron-embedded miRNAs that are released upon transduction of target cells. Exploiting such multigenic lentiviral vectors, we demonstrate robust miRNA-directed downregulation of vascular endothelial growth factor (VEGF) expression, leading to reduced angiogenesis, and parallel impairment of angiogenic pathways by codelivering the gene encoding pigment epithelium-derived factor (PEDF). Notably, subretinal injections of lentiviral vectors reveal efficient retinal pigment epithelium-specific gene expression driven by the VMD2 promoter, verifying that multigenic lentiviral vectors can be produced with high titers sufficient for in vivo applications. Altogether, our results suggest the potential applicability of combined miRNA- and protein-encoding lentiviral vectors in antiangiogenic gene therapy, including new combination therapies for amelioration of age-related macular degeneration.
机译:带有多个基因盒的基于慢病毒的基因传递载体在基因转移研究和基因治疗中是强大的工具,可实现多种治疗因子和荧光报告基因的共表达。从单个载体表达转基因和微小RNA(miRNA)簇的当前策略具有某些局限性,影响转基因表达水平和/或载体效价。在这项研究中,我们描述了一种新型的载体设计,该载体可促进治疗性基于RNA和蛋白质的抗血管生成因子以及背靠背RNApolII驱动表达盒的荧光报告基因的联合表达。这种配置可以有效产生内含子的miRNA,这些miRNA在转导靶细胞后释放。利用这种多基因慢病毒载体,我们证明了通过编码编码色素上皮衍生因子(PEDF)的基因,miRNA定向下调了血管内皮生长因子(VEGF)的表达,从而导致血管生成减少和血管生成途径的平行损伤。值得注意的是,慢病毒载体的视网膜下注射揭示了由VMD2启动子驱动的有效的视网膜色素上皮特异性基因表达,证明了多基因慢病毒载体可以高滴度生产,足以用于体内应用。总而言之,我们的结果表明,组合的编码miRNA和蛋白质的慢病毒载体在抗血管生成基因治疗中的潜在适用性,包括用于改善年龄相关性黄斑变性的新组合治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号